Can a Two-Drug combo shrink Hard-to-Treat thyroid tumors?
NCT ID NCT03099356
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This phase II trial is testing whether two drugs, cyclophosphamide and sirolimus, can help people with metastatic thyroid cancer that has stopped responding to radioactive iodine treatment. Participants take both drugs in monthly cycles, and doctors monitor tumor size and side effects. The goal is to see if the combination can shrink or control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cyclophosphamide and sirolimus
- What this could lead to
- If effective, this combination could offer a new treatment option for people with advanced thyroid cancer that no longer responds to standard radioactive iodine therapy.
- What could go wrong
- This is a small, early-phase trial, so the treatment may not work for everyone and could cause side effects like toxicity. More research would be needed before it becomes a standard therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC DIFFERENTIATED THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.